指南与共识神经肿瘤

cIMPACT-NOW第8次更新:分子风险参数澄清及脑膜瘤WHO分级推荐

cIMPACT-NOW update 8: Clarifications on molecular risk parameters and recommendations for WHO grading of meningiomas.
指南 / 共识 · Neuro Oncol · 2025-01-01

脑膜瘤是最常见的原发性颅内肿瘤。2021年WHO中枢神经系统肿瘤分类首次引入分子分级参数,将TERT启动子致癌变异和CDKN2A/B纯合缺失作为CNS WHO 3级的标志。cIMPACT-NOW指导委员会召集工作组,对脑膜瘤分级中长期存在的问题及新分子参数证据进行澄清和评估,提供更标准化的形态学评估指导(尤其关于脑侵犯),明确推荐进行先进分子检测的场景,并提出对CNS WHO 1级形态但伴1p染色体臂缺失合并22q缺失和/或NF2致癌变异的病例分配CNS WHO 2级。

要点

  • 2021年WHO分类将TERT启动子变异和CDKN2A/B纯合缺失作为脑膜瘤CNS WHO 3级的分子标志。
  • cIMPACT-NOW更新提供更标准化的形态学评估指导,最突出的是关于脑侵犯的评估。
  • 对CNS WHO 1级形态但伴1p缺失合并22q缺失和/或NF2变异的病例,建议分配CNS WHO 2级。

核心结论

  • cIMPACT-NOW更新提供脑膜瘤分级指导,包括标准化形态学评估(尤其脑侵犯)、推荐先进分子检测的场景,以及将CNS WHO 1级形态但伴1p缺失合并22q缺失和/或NF2变异的病例分配为CNS WHO 2级。

研究设计与样本

  • cIMPACT-NOW指导委员会召集工作组,对脑膜瘤分级中长期存在的问题及新分子参数证据进行澄清和评估。

主要发现

  • 2021年WHO中枢神经系统肿瘤分类首次引入脑膜瘤分子分级参数,将TERT启动子致癌变异和CDKN2A/B纯合缺失作为CNS WHO 3级的标志。
  • cIMPACT-NOW更新提供更标准化的形态学评估和解读指导,最突出的是关于脑侵犯的评估。
  • cIMPACT-NOW更新提出对CNS WHO 1级形态但伴1p染色体臂缺失合并22q缺失和/或NF2致癌变异的病例分配CNS WHO 2级。

关键数值与推荐

  • TERT启动子致癌变异和CDKN2A/B纯合缺失作为脑膜瘤CNS WHO 3级的分子标志。
  • 对CNS WHO 1级形态但伴1p染色体臂缺失合并22q缺失和/或NF2致癌变异的病例,建议分配CNS WHO 2级。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Meningiomas are the most frequent primary intracranial tumors. Hence, they constitute a major share of diagnostic specimens in neuropathology practice. The 2021 WHO Classification of Central Nervous System Tumors ("CNS5") has introduced the first molecular grading parameters for meningioma with oncogenic variants in the TERT promoter and homozygous deletion of CDKN2A/B as markers for CNS WHO grade 3. However, after the publication of the new classification volume, clarifications were requested, not only on novel but also on long-standing questions in meningioma grading that were beyond the scope of the WHO "blue book." In addition, more recent research into possible new molecular grading parameters could not yet be implemented in the 2021 classification but constitutes a compelling body of literature. Hence, the consortium to inform molecular and practical approaches to CNS tumor taxonomy-not official WHO (cIMPACT-NOW) Steering Committee convened a working group to provide such clarification and assess the evidence of possible novel molecular criteria. As a result, this cIMPACT-NOW update provides guidance for more standardized morphological evaluation and interpretation, most prominently pertaining to brain invasion, identifies scenarios in which advanced molecular testing is recommended, proposes to assign CNS WHO grade 2 for cases with CNS WHO grade 1 morphology but chromosomal arm 1p deletion in combination with 22q deletion and/or NF2 oncogenic variants, and discusses areas in which the current evidence is not yet sufficient to result in new recommendations.

来源:Neuro Oncol,查看原文。版权归原作者所有。

引用

  1. Sahm F, Aldape KD, Brastianos PK, et al. cIMPACT-NOW update 8: Clarifications on molecular risk parameters and recommendations for WHO grading of meningiomas. Neuro Oncol. 2025. PMID: 39212325. doi:10.1093/neuonc/noae170

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。